Biedermann, Julia

Brain, Oliver

Compot, Elisabeta

Digby-Bell, Jonathan

Hart, Ailsa

Hayee, Bu'Hussain

Ibarra, Ana

Ibraheim, Hajir

Irving, Peter M

Jawad, Issrah

Kok, Klaartje Bel

Norman, Irena

Oppong, Philip

Parkes, Gareth

Parkes, Miles

Powell, Nick

Rimmer, Joanna

Samaan, Mark A

Segal, Jonathan

Srinivasan, Ashish

English

BACKGROUND: The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may be advantageous in older patients at greater risk of treatment-related complications. However, there is a paucity of data exploring the outcomes of vedolizumab in this group. Our objective was to determine the clinical effectiveness and safety of vedolizumab in older IBD patients within a real-world multicenter UK cohort. METHODS: A retrospective review of electronic records across 6 UK hospitals was undertaken to evaluate the clinical effectiveness and safety outcomes of vedolizumab in IBD patients aged ≥60 at start of therapy. Rates of clinical response, remission and corticosteroid-free remission were assessed at weeks 14 and 52, using validated clinical indices, and were compared to historical controls from real-world vedolizumab-treated cohorts unstratified by age. RESULTS: Of 74 patients aged 60 years or above (median 66 years), 48 were included in our effectiveness analysis (29 ulcerative colitis, 19 Crohn's disease). Rates of clinical response, remission and corticosteroid-free remission at week 14 were 64%, 48% and 30%, respectively. By week 52, the rates of clinical response, remission, and corticosteroid-free remission were 52%, 38%, and 32%, respectively. Six (8%) patients experienced adverse effects. Effectiveness and safety outcomes were comparable to those of age-unstratified vedolizumab-treated cohorts. CONCLUSION: Our 1-year outcome data suggests that vedolizumab is safe and effective in older IBD patients and broadly comparable to cohorts unselected by age

Apollo (Cambridge)

Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.

https://www.repository.cam.ac.uk/bitstream/1810/317062/1/Effectiveness%20and%20safety%20of%20vedolizumab%20in%20inflammatory%20bowel%20disease%20patients%20aged%2060%20and%20over%20an%20observational%20multicenter.pdf

Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.

Abstract

Similar works

Full text

Available Versions

Apollo (Cambridge)